Summary

Market Size & Trends

The Middle East liver cancer diagnostics market size was estimated at USD 268.10 million in 2024 and is projected to reach USD 466.42 million by 2033, growing at a CAGR of 6.35% from 2025 to 2033. The ME liver cancer diagnostics market is primarily driven by the high prevalence of HBV and HCV, with Egypt reporting some of the region’s highest infection burdens. Rising cases of metabolic dysfunction-associated fatty liver disease (MAFLD) and diabetes are accelerating incidence rates, particularly in Gulf countries. Despite progress in viral hepatitis treatment, chronic infection remains a key driver of hepatocellular carcinoma. Increasing investments in advanced diagnostic technologies, including liquid biopsy, NGS, and AI-driven platforms, along with national cancer control programs and improved registries, are further fueling market growth by supporting early detection and better patient outcomes.

The Middle East liver cancer diagnostics market is expanding rapidly, driven by epidemiological trends, strategic alliances, and accelerated adoption of advanced technologies. Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to rise across the region, with different etiological patterns shaping country-level dynamics. Egypt has long borne the burden of hepatitis C-driven liver cancer, while Gulf states such as Saudi Arabia, the UAE, Kuwait, and Qatar are witnessing increasing cases linked to obesity, diabetes, and metabolic syndrome. This epidemiological transition underscores the pressing need for sensitive, non-invasive diagnostic tools, supported by public health initiatives and stronger cancer registries. Despite progress in viral hepatitis management, lifestyle-related drivers continue to fuel incidence, requiring diagnostics that can enable earlier detection and intervention.

The competitive landscape is being reshaped by global biotech firms and regional healthcare leaders. In October, 2024, Helio Genomics entered a strategic partnership with Halub Medical Co. to commercialize HelioLiver Dx in Saudi Arabia and the broader GCC. The test, expected to be launched commercially in Q1 2025, is projected to generate more than USD 10 million in revenue in its first year of availability. HelioLiver Dx leverages AI-driven multi-analyte technology-analyzing cfDNA, methylation signatures, serum proteins, and demographic markers and demonstrated four-times higher sensitivity than ultrasound in pivotal U.S. trials led by Stanford Medical Centers. Importantly, it offers adherence rates nearly nine-times greater than conventional surveillance, addressing a critical gap in patient compliance across the Middle East. The partnership aligns with Saudi Arabia’s Health Cluster initiatives and Vision 2030 strategy, reflecting how international innovation is being localized to address regional healthcare burdens.

Middle East Liver Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the Middle East liver cancer diagnostics market report on the basis of test type, end-use, country:

• Middle East Liver Cancer Diagnostics Test type Outlook (Revenue, USD Million, 2021 - 2033)
• Laboratory Tests
o Biomarkers
o Oncofetal and Glycoprotein Antigens
o Enzymes and Isoenzymes
o Growth Factors and Receptors
o Molecular Markers
o Pathological Biomarkers
o Blood Tests
• Imaging
• Endoscopy
• Biopsy
• Middle East Liver Cancer Diagnostics End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & CRO Laboratories
• Country Outlook (Revenue in USD Million, 2021 - 2033)
• Middle East
o Saudi Arabia
o UAE
o Kuwait
o Qatar
o Oman
o Rest of MEA

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test type
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test type outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Middle East Liver Cancer Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Incidence of Liver Cancer
3.2.1.2. Technological Advancements
3.2.1.3. Extensive R&D For Developing Novel Testing Solutions
3.2.2. Market restraint analysis
3.2.2.1. High Cost of Diagnostic imaging
3.3. Middle East Liver Cancer Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Middle East Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Liver Cancer Diagnostics Market: Product Movement Analysis
4.3. Middle East Liver Cancer Diagnostics Market Size & Trend Analysis, by test type, 2021 to 2033 (USD Million)
4.3.1. Laboratory Tests Market, 2021 - 2033 (USD MILLION)
4.3.1.1. Biomarkers
4.3.1.1.1. Biomarkers market, 2021 - 2033 (USD million)
4.3.1.1.1.1. Oncofetal and Glycoprotein Antigens
4.3.1.1.1.1.1. Oncofetal and glycoprotein antigens market, 2021 - 2033 (USD million)
4.3.1.1.1.2. Enzymes and Isoenzymes
4.3.1.1.1.2.1. Enzymes and isoenzymes market, 2021 - 2033 (USD million)
4.3.1.1.1.3. Growth Factors and Receptors
4.3.1.1.1.3.1. Growth factors and receptors market, 2021 - 2033 (USD million)
4.3.1.1.1.4. Molecular Markers
4.3.1.1.1.4.1. Molecular markers market, 2021 - 2033 (USD million)
4.3.1.1.1.5. Pathological Biomarkers
4.3.1.1.1.5.1. Pathological biomarkers market, 2021 - 2033 (USD million)
4.3.1.2. Blood Tests
4.3.1.2.1. Blood tests market, 2021 - 2033 (USD million)
4.3.2. Imaging
4.3.2.1. Imaging Market, 2021 - 2033 (USD MILLION)
4.3.3. Endoscopy
4.3.3.1. Endoscopy Market, 2021 - 2033 (USD MILLION)
4.3.4. Biopsy
4.3.4.1. Biopsy Market, 2021 - 2033 (USD MILLION)
Chapter 5. Middle East Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis
5.1. End Use Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Middle East Liver Cancer Diagnostics Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Hospitals & Diagnostic Laboratories
5.5.1. Hospitals & Diagnostic Laboratories market, 2021 - 2033 (USD Million)
5.6. Academic & Research Institutes
5.6.1. Academic & Research Institutes Market, 2021 - 2033 (USD million)
5.7. Pharmaceutical & CRO Laboratories
5.7.1. Pharmaceutical & CRO Laboratories market, 2021 - 2033 (USD million)
Chapter 6. Middle East Liver Cancer Diagnostics Market: Country Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
6.5. ME
6.5.1. Saudi Arabia
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/Reimbursement
6.5.1.3. Competitive scenario
6.5.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
6.5.2. UAE
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/Reimbursement
6.5.2.3. Competitive scenario
6.5.2.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
6.5.3. Kuwait
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
6.5.4. Qatar
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/Reimbursement
6.5.4.3. Competitive scenario
6.5.4.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
6.5.5. Oman
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/Reimbursement
6.5.5.3. Competitive scenario
6.5.5.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. Abbott Laboratories
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Services benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Thermo Fisher Scientific, Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Services benchmarking
7.3.5.4. Strategic initiatives
7.3.6. F. Hoffmann-La Roche Ltd.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Services benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Qiagen N.V.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Services benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Siemens Healthineers
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Services benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Becton, Dickinson & Company
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Services benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Illumina, Inc.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Services benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Epigenomics AG
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Services benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Koninklijke Philips N.V.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Services benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Fujifilm Medical Systems U.S.A., Inc.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Services benchmarking
7.3.13.4. Strategic initiatives